Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Cuts 20 Percent of Workforce, Appoints New CEO

SAN FRANCISCO, Aug. 5 - Genaissance Pharmaceuticals today announced layoffs and the appointment of a new CEO while reporting an increase in second quarter revenue.

 

The company said it has initiated layoffs of 20 percent of its workforce, mainly from the company's DNA sequencing facility and related informatics staff. This brings total staff to 110 at the end of the second quarter, according to the company.

 

Newly appointed CEO Kevin Rakin, previously president and CFO, said in a statement that the layoffs are part of cost reduction in an environment where raising money in capital markets is difficult and the financial terms of various commercialization and partnership agreements are taking longer than expected.

 

The layoffs "should allow Genaissance to achieve a breakeven point in the next three years without a need to raise additional capital," said Rakin.

 

Rakin replaced Gualberto Ruano, a company founder and its CEO since its inception in 1997. Ruano was named chief scientific officer and vice chairman of the board of directors. The management change reflects the company's focus onto making deals, chairman of the board Jurgen Drews said in a statement.

 

In the same announcement, Genaissance reported total revenues of $1.9 million for the three months ended June 30 compared with $1.1 million for the same period one year ago.

 

Net loss for the quarter decreased to $7.5 million, or $.33 per share, compared to $13.2 million, or $.58 per share, for the year-ago period. Including a non-recurring write-down charge of $6 million related to excess equipment in the company's DNA sequencing facility, net loss rose slightly to $13.5 million, or $.59 per share, compared to $13.2 million, or $.58 per share, for the year-ago period.

 

R&D spending fell to approximately $6.6 million from $11.5 million for the second quarter in 2001

 

The company said it had roughly $42.2 million in cash, cash equivalents, and marketable securities as of June 30.

 

Click here for more information.

 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.